Empirical approach for improved estimation of unbound serum concentrations of valproic acid in epileptic infants by considering their physical development

Satoshi Ueshima, Tetsuya Aiba, Tomoaki Sato, Hisashi Matsunaga, Yuji Kurosaki, Yoko Ohtsuka, Toshiaki Sendo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The unbound serum concentration of valproic acid (VPA) is closely related to its therapeutic efficacy. In epileptic infants, the unbound VPA concentration varies largely from patient to patient, being difficult to predict using the reported equations for older children. To establish an equation to estimate the unbound concentration in infants, we empirically characterized the relationship between total and unbound VPA concentrations, taking their growth and development into consideration. Data were retrospectively collected from archived clinical records of 30 epileptic infants aged 0-11 months old. The relationship between total and unbound VPA concentrations was analyzed according to the Langmuir equation, in which the patient's body weight, height, and body surface area were considered as physical development indices. Inter- and intra-individual variabilities in the VPA concentrations were also considered. It was shown that the unbound VPA concentration in infants is properly estimated when their body weights are taken into account, in which the parameter for the maximum binding site concentration (Bm) increases as the body weight increases, while that for the dissociation constant (Kd) is unaltered. Additionally, the relationship was shown to slightly change when the infants are concomitantly treated with VPA and the other antiepileptics. These findings provide useful information to adjust the VPA dosage to achieve optimal therapeutic efficacy in epileptic infants.

Original languageEnglish
Pages (from-to)108-113
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume34
Issue number1
DOIs
Publication statusPublished - 2011

Fingerprint

Valproic Acid
Serum
Body Weight
Body Height
Body Surface Area
Growth and Development
Anticonvulsants
Binding Sites
Therapeutics

Keywords

  • Body weight
  • Development
  • Infant
  • Protein binding
  • Therapeutic drug monitoring
  • Valproic acid

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Cite this

Empirical approach for improved estimation of unbound serum concentrations of valproic acid in epileptic infants by considering their physical development. / Ueshima, Satoshi; Aiba, Tetsuya; Sato, Tomoaki; Matsunaga, Hisashi; Kurosaki, Yuji; Ohtsuka, Yoko; Sendo, Toshiaki.

In: Biological and Pharmaceutical Bulletin, Vol. 34, No. 1, 2011, p. 108-113.

Research output: Contribution to journalArticle

@article{bff43ae3333a47108970f556d09713dc,
title = "Empirical approach for improved estimation of unbound serum concentrations of valproic acid in epileptic infants by considering their physical development",
abstract = "The unbound serum concentration of valproic acid (VPA) is closely related to its therapeutic efficacy. In epileptic infants, the unbound VPA concentration varies largely from patient to patient, being difficult to predict using the reported equations for older children. To establish an equation to estimate the unbound concentration in infants, we empirically characterized the relationship between total and unbound VPA concentrations, taking their growth and development into consideration. Data were retrospectively collected from archived clinical records of 30 epileptic infants aged 0-11 months old. The relationship between total and unbound VPA concentrations was analyzed according to the Langmuir equation, in which the patient's body weight, height, and body surface area were considered as physical development indices. Inter- and intra-individual variabilities in the VPA concentrations were also considered. It was shown that the unbound VPA concentration in infants is properly estimated when their body weights are taken into account, in which the parameter for the maximum binding site concentration (Bm) increases as the body weight increases, while that for the dissociation constant (Kd) is unaltered. Additionally, the relationship was shown to slightly change when the infants are concomitantly treated with VPA and the other antiepileptics. These findings provide useful information to adjust the VPA dosage to achieve optimal therapeutic efficacy in epileptic infants.",
keywords = "Body weight, Development, Infant, Protein binding, Therapeutic drug monitoring, Valproic acid",
author = "Satoshi Ueshima and Tetsuya Aiba and Tomoaki Sato and Hisashi Matsunaga and Yuji Kurosaki and Yoko Ohtsuka and Toshiaki Sendo",
year = "2011",
doi = "10.1248/bpb.34.108",
language = "English",
volume = "34",
pages = "108--113",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "1",

}

TY - JOUR

T1 - Empirical approach for improved estimation of unbound serum concentrations of valproic acid in epileptic infants by considering their physical development

AU - Ueshima, Satoshi

AU - Aiba, Tetsuya

AU - Sato, Tomoaki

AU - Matsunaga, Hisashi

AU - Kurosaki, Yuji

AU - Ohtsuka, Yoko

AU - Sendo, Toshiaki

PY - 2011

Y1 - 2011

N2 - The unbound serum concentration of valproic acid (VPA) is closely related to its therapeutic efficacy. In epileptic infants, the unbound VPA concentration varies largely from patient to patient, being difficult to predict using the reported equations for older children. To establish an equation to estimate the unbound concentration in infants, we empirically characterized the relationship between total and unbound VPA concentrations, taking their growth and development into consideration. Data were retrospectively collected from archived clinical records of 30 epileptic infants aged 0-11 months old. The relationship between total and unbound VPA concentrations was analyzed according to the Langmuir equation, in which the patient's body weight, height, and body surface area were considered as physical development indices. Inter- and intra-individual variabilities in the VPA concentrations were also considered. It was shown that the unbound VPA concentration in infants is properly estimated when their body weights are taken into account, in which the parameter for the maximum binding site concentration (Bm) increases as the body weight increases, while that for the dissociation constant (Kd) is unaltered. Additionally, the relationship was shown to slightly change when the infants are concomitantly treated with VPA and the other antiepileptics. These findings provide useful information to adjust the VPA dosage to achieve optimal therapeutic efficacy in epileptic infants.

AB - The unbound serum concentration of valproic acid (VPA) is closely related to its therapeutic efficacy. In epileptic infants, the unbound VPA concentration varies largely from patient to patient, being difficult to predict using the reported equations for older children. To establish an equation to estimate the unbound concentration in infants, we empirically characterized the relationship between total and unbound VPA concentrations, taking their growth and development into consideration. Data were retrospectively collected from archived clinical records of 30 epileptic infants aged 0-11 months old. The relationship between total and unbound VPA concentrations was analyzed according to the Langmuir equation, in which the patient's body weight, height, and body surface area were considered as physical development indices. Inter- and intra-individual variabilities in the VPA concentrations were also considered. It was shown that the unbound VPA concentration in infants is properly estimated when their body weights are taken into account, in which the parameter for the maximum binding site concentration (Bm) increases as the body weight increases, while that for the dissociation constant (Kd) is unaltered. Additionally, the relationship was shown to slightly change when the infants are concomitantly treated with VPA and the other antiepileptics. These findings provide useful information to adjust the VPA dosage to achieve optimal therapeutic efficacy in epileptic infants.

KW - Body weight

KW - Development

KW - Infant

KW - Protein binding

KW - Therapeutic drug monitoring

KW - Valproic acid

UR - http://www.scopus.com/inward/record.url?scp=78951481248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78951481248&partnerID=8YFLogxK

U2 - 10.1248/bpb.34.108

DO - 10.1248/bpb.34.108

M3 - Article

C2 - 21212527

AN - SCOPUS:78951481248

VL - 34

SP - 108

EP - 113

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 1

ER -